Amneal Pharmaceuticals, Inc.
NASDAQ:AMRXDrug Manufacturers - Specialty & Generic
-$0.15 today
- Market cap
- $7.62B
- Beta
- 1.32
- P/E (TTM)
- 43.4
- EPS (TTM)
- $0.37
Volume 1.91M
Average 1.75M
AMRX Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Amneal Pharmaceuticals, Inc.NASDAQ: AMRX
Net Margin · Q2 FY2026 · quarter ended Jun 2026
Net margin widens to 7.2%
Net margin was 7.2% in Q2 FY2026, up 4.1 pp from a year earlier. On a trailing-twelve-month basis it was 5.0%, up 4.9 pp year over year. Over 3 fiscal years it widened by 8.3 pp.
Context
- Net margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 5 analysts of 10.8% for the fiscal year ending Dec 2026, up from 2.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 7.2%-1.4 pp QoQ
- Last fiscal yearDec 2025
- 2.4%+6.6 pp YoY
- LTMJun 2026
- 5.0%+4.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +4.1 pp | +9.4 pp | +5.3 pp |
| 1 year | +6.6 pp | +8.4 pp | +1.8 pp |
| 3 years | +8.3 pp | +11.2 pp | +3.0 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 2.4%
- Year-over-year change
- +6.6pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.4% | +6.6pp |
| FY2024 | 2024-12-31 | -4.2% | -0.7pp |
| FY2023 | 2023-12-31 | -3.5% | +2.4pp |
| FY2022 | 2022-12-31 | -5.9% | -6.4pp |
| FY2021 | 2021-12-31 | 0.5% | — |
Net Margin vs competitors
How AMRX compares with its peers on the latest reported figures
- AMRX's LTM Jun 2026 net margin of 5.0% is the 5th highest of the 11 companies compared; the peer median is 1.4%.
- Its year-over-year change of +4.9 pp is the 6th highest of 11, against a peer median of -1.7 pp.
- Over three fiscal years its change of +8.3 pp compares with a peer median of +5.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
INDVIndivior Pharmaceuticals Inc | LTM Jun 2026 | 26.7% | +15.7 pp | +21.8 pp |
| LTM Mar 2026 | 11.0% | -8.5 pp | -4.7 pp | |
| LTM Mar 2026 | 9.7% | +12.8 pp | +24.0 pp | |
| LTM Sep 2026 | 8.5% | -8.7 pp | -5.6 pp | |
| LTM Jun 2026 | 5.0% | +4.9 pp | +8.3 pp | |
| LTM Jun 2026 | 4.1% | +5.0 pp | +24.6 pp | |
| LTM Mar 2026 | -1.3% | +12.4 pp | +26.0 pp | |
| LTM Jun 2026 | -2.8% | +21.8 pp | -37.4 pp | |
| LTM Jun 2026 | -10.1% | -11.1 pp | +4.3 pp | |
| LTM Mar 2026 | -17.2% | -9.3 pp | +6.9 pp | |
| LTM Jun 2026 | -41.9% | -40.0 pp | -30.4 pp | |
| Peer median (excluding AMRX) | 1.4% | -1.7 pp | +5.6 pp | |
Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.09B | 2.21B | 2.39B | 2.79B | 3.02B |
| Cost of Revenue | 1.32B | 1.42B | 1.53B | 1.77B | 1.88B |
| Gross Profit | 768.97M | 791.46M | 863.87M | 1.02B | 1.14B |
| Gross Margin | 36.7% | 35.8% | 36.1% | 36.5% | 37.6% |
| Research & Development | 209.56M | 208.66M | 194.75M | 190.71M | 186.18M |
| Selling, General & Admin | 365.5M | 399.7M | 429.68M | 476.44M | 526.83M |
| Operating Expenses | 616.26M | 886.39M | 659.5M | 771.11M | 713M |
| Depreciation & Amortization | 233.41M | 240.18M | 229.4M | 236.19M | 223.57M |
| EBITDA | 401.1M | 440.21M | 500.78M | 439.77M | 603.87M |
| EBITDA Margin | 19.2% | 19.9% | 20.9% | 15.7% | 20.0% |
| Operating Income | 152.72M | (94.93M) | 204.37M | 249.33M | 423.09M |
| Operating Margin | 7.3% | -4.3% | 8.5% | 8.9% | 14.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 136.33M | 158.38M | 210.63M | 258.6M | 241.09M |
| Other Income / Expenses | (121.35M) | (153.2M) | (244.64M) | (304.34M) | (283.88M) |
| Income Before Tax | 31.37M | (248.13M) | (40.27M) | (55.01M) | 139.21M |
| Pre-Tax Margin | 1.5% | -11.2% | -1.7% | -2.0% | 4.6% |
| Income Tax Expense | 11.2M | 6.66M | 8.45M | 18.86M | 11.28M |
| Net Income | 10.62M | (129.99M) | (83.99M) | (116.89M) | 72.06M |
| Net Margin | 0.5% | -5.9% | -3.5% | -4.2% | 2.4% |
| EPS (Basic) | 0.07 | (0.86) | (0.48) | (0.38) | 0.23 |
| EPS (Diluted) | 0.07 | (0.86) | (0.48) | (0.38) | 0.22 |
| Weighted Avg Shares | 148.92M | 150.94M | 174.99M | 308.98M | 313.37M |
| Weighted Avg Shares (Diluted) | 151.82M | 150.94M | 176.14M | 308.98M | 324.81M |
Amneal Pharmaceuticals, Inc.
NASDAQ:AMRX
Intrinsic Alpha fair value
Locked
Current Price
$21.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.